Keywords
Calcitonin gene-related peptide
Monoclonal antibodies
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the efficacy and safety of anti-CGRP monoclonal antibodies for the prevention of episodic and chronic migraine, considering their effects on attack frequency, acute medication use, disability and quality of life. Methods: This is an integrative literature review with a descriptive design and qualitative approach, conducted in PubMed, Virtual Health Library and Cochrane Library databases. The guiding question was structured according to the PICO strategy, including adult patients with episodic or chronic migraine, use of erenumab, fremanezumab, galcanezumab or eptinezumab, comparison with placebo or conventional preventive treatments, and clinical, functional and safety outcomes. Full-text original articles were included, resulting in 16 selected studies. Results: Anti-CGRP antibodies reduced monthly migraine and headache days, increased clinical response rates, decreased acute medication use and improved functional outcomes. The most frequent adverse events were injection-site reactions, nasopharyngitis, fatigue and constipation. Final considerations: Anti-CGRP antibodies show favorable evidence for migraine prevention and an acceptable safety profile in the studies analyzed, although longer follow-up in special populations is required.
References
ASHINA M, et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia, 2020; 40(3): 241–254.
ASHINA M, et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet Neurology, 2022; 21(7): 597–607.
BARNES S, et al. Calcitonin gene-related peptide–targeted therapies for migraine. Australian Prescriber, 2025; 48(2): 40–46.
DETKE HC, et al. Galcanezumab in chronic migraine. Neurology, 2018; 91(24): e2221.
DODICK DW, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine. JAMA, 1999; 319(19): 1999.
FERRARI MD, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet, 2019; 394(10203): 1030–1040.
ELLER MT, et al. CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke. Neurology, 2025; 105: 2.
GOADSBY PJ, et al. A Controlled Trial of Erenumab for Episodic Migraine. New England Journal of Medicine, 2017; 377(22): 2123–2132.
IANNONE LF, et al. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score. CNS Drugs, 2022; 36(2): 191–202.
LIPTON RB, et al. Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder. JAMA Neurology, 2025.
LIPTON RB, et al. Efficacy and safety of eptinezumab in patients with chronic migraine. Neurology, 2020; 94(13): e1365–e1377.
MULLENERS WM, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet Neurology, 2020; 19(10): 814–825.
ORLANDO B, et al. Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence. Brain Sciences, 2024; 14(9): 948–948.
PAVELIC AR, et al. Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data. Cells, 2022; 12(1): 143.
POZO-ROSICH P, et al. Early Use of Erenumab vs Nonspecific Oral Migraine Preventives. JAMA Neurology, 2024; 81(5): 461–461.
REUTER U, et al. Erenumab versus topiramate: migraine‐related disability, impact and health‐related quality of life. European Journal of Neurology, 2024; 31(12).
SILBERSTEIN SD, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. New England Journal of Medicine, 2017; 377(22): 2113–2122.
SKLJAREVSKI V, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia, 2018; 38(8): 1442–1454.
SOUZA MT, et al. Revisão integrativa: o que é e como fazer. Einstein, 2010; 8(1): 102–108.
STAUFFER VL, et al. Evaluation of Galcanezumab for the Prevention of Episodic Migraine. JAMA Neurology, 2018; 75(9): 1080.
TOBIN JÁ, et al. Reductions in acute medication use and healthcare resource utilization in patients with
chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN). Journal of Medical Economics, 2022; 25(1): 1030–1038.
YU S, et al. Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study. BMC neurology, 2023; 23(1): 441